Carna Biosciences, Inc. reported consolidated and non-consolidated earnings results for the year ended December 31, 2020. For the year, on consolidated basis, the company reported net sales of JPY 1,133 million compared to JPY 3,207 million a year ago. Operating loss was JPY 1,057 million compared to operating profit of JPY 977 million a year ago. Loss attributable to owners of parent was JPY 1,111 million compared to profit of JPY 828 million a year ago. Basic loss per share was JPY 90.33 compared to basic earnings per share of JPY 76.05 a year ago. Loss was JPY 1,111,032,000 compared to profit of JPY 828,289,000 a year ago. For the year, on non-consolidated basis, the company reported net sales of JPY 1,042 million compared to JPY 3,070 million a year ago. Operating loss was JPY 1,057 million compared to operating profit of JPY 898 million a year ago. Loss was JPY 1,129 million compared to profit of JPY 745 million a year ago. Basic loss per share was JPY 91.84 compared to basic earnings per share of JPY 68.47 a year ago.